<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872766</url>
  </required_header>
  <id_info>
    <org_study_id>15 7714 03</org_study_id>
    <nct_id>NCT02872766</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Corneal Cross Linking for the Treatment of Myopia.</brief_title>
  <acronym>CXLMyopie</acronym>
  <official_title>A Pilot Evaluation of the Safety and Efficacy of Topographically Customized Corneal Cross Linking for the Treatment of Myopia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      43 Subjects (43 eyes) qualified for participation will undergo the required screening&#xD;
      procedures to determine study eligibility. The surgical protocol involves applying riboflavin&#xD;
      0,22% to 0,25 % up to 20 minutes . Then, the eyes will be exposed to UVA (ultraviolet A)&#xD;
      light with the KXL II system according to the programmed treatment pattern.&#xD;
&#xD;
      All use of the KXL II system will be in accordance with the general instructions in the&#xD;
      operator's manual. All subjects will be evaluated at screening, Day 3, and 1, 3, 6 ,12 and 24&#xD;
      months after treatment.&#xD;
&#xD;
      Manual keratometry, manifest refraction, uncorrected visual acuity, best corrected visual&#xD;
      acuity, slit lamp biomicroscopy, pentacam measurements and placido disc topography (TMS),&#xD;
      will be obtained at baseline and at appropriate times after the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of efficacy&#xD;
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected visual acuity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in manifest refraction spherical equivalent from baseline</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in corneal curvature from baseline</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Corneal cross linking (CXL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CXL Myopia</intervention_name>
    <description>Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.</description>
    <arm_group_label>Corneal cross linking (CXL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  Willingness to follow all instructions and comply with schedule for follow up visits&#xD;
&#xD;
          -  Having myopia with manifest refraction spherical equivalent of -1.00 to -2.50 D, with&#xD;
             cylindrical component pl to -0.75 D&#xD;
&#xD;
          -  Social security insurance or equivalent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  sensitivity to the use of the test article(s)&#xD;
&#xD;
          -  hypersensitivity to local anesthesics&#xD;
&#xD;
          -  Corneal pachymetry that is &lt; 480 microns&#xD;
&#xD;
          -  Eyes with keratoconus&#xD;
&#xD;
          -  Eyes which are aphakic or with corneal intacs&#xD;
&#xD;
          -  Previous ocular condition (other than refractive error) in the eye to be treated that&#xD;
             may predispose the eye for future complications. For example: History of corneal&#xD;
             disease (e.g., herpes simplex, recurrent erosion syndrome, corneal dystrophy,&#xD;
             refractive keratotomy etc.), clinically significant corneal scarring in the&#xD;
             crosslinking treatment zone&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Patients with a current condition that, in the investigator's opinion, would interfere&#xD;
             with or prolong epithelial healing&#xD;
&#xD;
          -  Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking&#xD;
             treatment.&#xD;
&#xD;
          -  Juridical protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fran√ßois MALECAZE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

